Literature DB >> 6084430

Serologic and clinical responses of premunized, vaccinated, and previously infected cattle to challenge exposure by two different Anaplasma marginale isolates.

K L Kuttler, J L Zaugg, L W Johnson.   

Abstract

Two Anaplasma marginale isolates, one originating in Florida (FAM) and the other from Virginia (VAM), were compared immunologically by cross-challenge exposure of 14 Anaplasma carrier cattle, 8 previously infected cattle, and 6 splenectomized carrier calves. In addition, 28 cattle vaccinated with a commercially available adjuvant killed vaccine and 22 nonvaccinated cattle were challenge exposed with either FAM or VAM. A detectable clinical response was not produced by either FAM or VAM challenge exposure in carrier and previously infected cattle; however, evidence of A marginale growth as characterized by low percentages of parasitemia and increased serum complement-fixation titers was seen in carrier cattle given a heterologous challenge organism and in previously infected cattle inoculated with either homologous or heterologous organisms. Among splenectomized calves, there was virtually no cross protection to the heterologous challenge exposure, whereas a homologous challenge failed to elicit any detectable response. Vaccinated cattle were resistant to VAM exposure, but the clinical response to FAM exposure was severe with a 47% mortality. Most of these cattle displayed typical acute anaplasmosis that was only marginally less severe than that encountered in nonvaccinated cattle.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6084430

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  17 in total

1.  Crossprotective immunity between the Florida and a Zimbabwe stock of Anaplasma marginale.

Authors:  N Tebele; G H Palmer
Journal:  Trop Anim Health Prod       Date:  1991-11       Impact factor: 1.559

2.  Immunization of cattle with the MSP-1 surface protein complex induces protection against a structurally variant Anaplasma marginale isolate.

Authors:  G H Palmer; A F Barbet; G H Cantor; T C McGuire
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

3.  Arg-gingipain a DNA vaccine induces protective immunity against infection by Porphyromonas gingivalis in a murine model.

Authors:  H Yonezawa; K Ishihara; K Okuda
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

4.  A new PCR-RFLP method for detection of Anaplasma marginale based on 16S rRNA.

Authors:  Vahid Noaman; Parviz Shayan
Journal:  Vet Res Commun       Date:  2009-12-15       Impact factor: 2.459

Review 5.  Antigens and alternatives for control of Anaplasma marginale infection in cattle.

Authors:  Katherine M Kocan; José de la Fuente; Alberto A Guglielmone; Roy D Meléndez
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

6.  Immunization of cattle with a 36-kilodalton surface protein induces protection against homologous and heterologous Anaplasma marginale challenge.

Authors:  G H Palmer; S M Oberle; A F Barbet; W L Goff; W C Davis; T C McGuire
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

7.  Molecular size variations in an immunoprotective protein complex among isolates of Anaplasma marginale.

Authors:  S M Oberle; G H Palmer; A F Barbet; T C McGuire
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

8.  Dynamics of Anaplasma marginale in splenectomised calves treated with either imidocarb or oxytetracycline.

Authors:  K L Kuttler
Journal:  Trop Anim Health Prod       Date:  1986-05       Impact factor: 1.559

9.  Identification of Anaplasma marginale long-term carrier cattle by detection of serum antibody to isolated MSP-3.

Authors:  T C McGuire; W C Davis; A L Brassfield; T F McElwain; G H Palmer
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

10.  Immunization-induced Anaplasma marginale-specific T-lymphocyte responses impaired by A. marginale infection are restored after eliminating infection with tetracycline.

Authors:  Joshua E Turse; Glen A Scoles; James R Deringer; Lindsay M Fry; Wendy C Brown
Journal:  Clin Vaccine Immunol       Date:  2014-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.